Erythropoietin therapy in chronic uremia: The impact of normalization of hematocrit

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 5, 1999, Pages 573-578

  Murphy, Stephen T ^b   Parfrey, Patrick S ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; DRUG EFFECT; HEMATOCRIT; HEMODIALYSIS; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UREMIA; VASCULAR ACCESS;

ANEMIA; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COGNITION; ERYTHROPOIETIN, RECOMBINANT; EXERCISE; HEMATOCRIT; HUMANS; IRON; RENAL DIALYSIS; UREMIA;

EID: 0033404503     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199909000-00007     Document Type: Review

References (50)

1. 1 Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321:158-163.
2. 2 McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992; 12:162-169.
3. 3 Eschbach JW, et al. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30( 4 Suppl 3):S192-S240. NKF-DOQI clinical practice guidelines. Guidelines are also available on the internet at http://www.kidney.org/professionals/doqi/doqi/.
4. 4 Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10:1309-1316. This large retrospective study compares risk of hospitalization in hemodialysis patients stratified by hematocrit, and demonstrates the lowest risk in the 33-36% group.
5. 5 Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610-619. This large retrospective study reports the association of mortality with stratified hematocrit level, and suggests hemodialysis patients with hematocrit levels of 33-36% have the lowest risk of cardiac and all cause mortality.
6. 6 Kratz A, Lewandrowski KB. Case records of the Massachusetts general hospital. Weekly clinicopathological exercises. Normal reference laboratory values. N Engl J Med 1998; 339:1063-1072.
7. 7 Levin NW. Quality of life and hematocrit level. Am J Kidney Dis 1992;S1:16-20.
8. 8 The Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. BMJ 1990; 300:573-578.
9. 9 Eschbach JW, Glenny R, Robertson T. Normalizing hematocrit in hemodialysis patients with EPO improves quality of life and is safe. J Am Soc Nephrol 1993; 4:445.
10. 10 Valderrabano F. Quality of life and hematocrit in hemodialysis patients. A prospective multicentre study. Second European Epoetin Symposium, Crete, Greece. April 1998.
11. 11 Besarb A, Bolton K, Browne JK, Egrie JC et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epotin. N Engl J Med 1998; 339:584-590. This outstanding randomized controlled clinical trial of 1233 hemodialysis patients with symptomatic cardiac disease was terminated early because of increased mortality and increased vascular access loss in the group allocated to normalization of hematocrit with EPO.
12. 12 Wells GA, Coyle D, Lee KM, et al. Quality of life effects of normalization of hemoglobin in asymptomatic hemodialysis patients [abstract]. J Am Soc Nephrol 1998; 9:230A.
13. 13 Robertson HT, Haley NR, Guthrie M, Cardenas D, Eschbach JW, Adamson JW. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 1990; 15:325-332.
14. 14 Guthrie M, Cardenas D, Eschbach JW, Haley NR, Robertson HT, Evans RW. Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 1990; 39:97-102.
15. 15 Stray-Gunderson J, Sams B, Goodkin D, Holloway D, Wang C, Thompson J. Improvement in functional capacity in dialysis patients with regular exercise and correction of anemia [abstract]. J Am Soc Nephrol 1997; 8:212A.
16. 16 Barany P, Svendenhab J, Freyschuss U, Bergstrom J. Physiologic effects of correcting anemia in hemodialysis patients to a normal hemoglobin concentration [abstract]. Clin Invest 1994; 72:B13.
17. 17 Suzuki M, Tsutsui M, Yokahama A, Hirasawa Y. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities. Artif Organs 1995; 19:1258.
18. 18 Foley RN, Parfrey PS, Harnett JD, Kent G, Martin CJ, Murray D, Barre PE. Clinical and echocardiographic cardiovascular disease in patients starting end-stage renal therapy: prevalence, association, and prognosis. Kidney Int 1995; 47:186-192.
19. 19 Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11:1277-1285.
20. 20 Foley RN, Parfrey PS, Kent GM, Murray DC, Barre PE. The long term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54:1720-1724. This prospective cohort study of cardiac disease in dialysis patients identified 29 selected patients who had 4 serial echocardiograms. Progressive left ventricular dilatation and hypertrophy was characteristic, and was associated with anemia and mode of dialysis therapy.
21. 21 Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995; 9:908-914.
22. 22 Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcomes and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996; 49:1428-1434.
23. 23 Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Cardiac disease in diabetic end stage renal disease. Diabetologia 1997; 40:1307-1312.
24. 24 Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis, and risk factors. Kidney Int 1995; 47:884-890.
25. 25 Levin A, Thompson CR, Ethier J, Carlisle E, Tobe S, Mendelsson D, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34:125-134. This prospective cohort study of predialysis patients with chronic renal insufficiency identifies anemia as an independent risk factor for left ventricular growth.
26. 26 Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28:53-61.
27. 27 Foley RN, Parfrey PS, Morgan J, et al. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation. J Am Soc Nephrol 1998; 9:208A.
28. 28 Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Left ventricular geometry: a critical prognostic variable in ESRD patients. J Am Soc Nephrol 1995; 5:2024-2031.
29. 29 Sagales T, Gimeno V, Planella MJ, Raguer N, Bartolome SK. Effects of rHuEPO on Q-EEG and event related potentials in chronic renal failure. Kidney Int 1993; 44:1109-1115.
30. 30 Nissenson AR, Marsh JT, Brown WS, et al. Central nervous system function in dialysis patients: a practical approach. Semin Dial 1991; 4:115-123.
31. 31 Marsh JT, Brown WS, Wolcott D, Landsverk J, Nissenson AR. Electrophysiological indices of central nervous system function in hemodialysis and CARD. Kidney Int 1986; 34:397-402.
32. 32 Souheaver GT, Ryan JJ, DeWolfe AS. Neuropsychological patterns in uremia. J Clin Psychol 1982; 38:490-496.
33. 33 Osberg JW, Meares GJ, McKee DC, Burnett GB. Intellectual functioning in renal failure and chronic dialysis. J Chronic Dis 1982; 25:445-457.
34. 34 Ratner DP, Adams KM, Levin NW, Rourke BP. Effects of hemodialysis on the cognitive and sensory-motor functioning of the adult chronic hemodialysis patient. J Behav Med 1983; 6:291-311.
35. 35 Nissenson AR. Epotin and cognitive function. Am J Kidney Dis 1992; 1(S1):21-24.
36. 36 Kramer L, Madl C, Stockenhuber F, Yeganehfar W, Eisenhuber E, Derfler K, et al. Beneficial effect of renal transplantation on cognitive brain function. Kidney Int 1996; 49:833-838.
37. 37 Grimm G, Stockenhuber F, Schneweiss B, Madl C, Zeithofer J, Schneider B. Improvement in brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990; 38:480-486.
38. 38 Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Inl 1991; 39:155-163.
39. 39 Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; 14:478-485.
40. 40 Metry G, Wikstrom B, Valind S, et al. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 1999; 10:854-863. This interesting paper reports the effects of normalization of hematocrit on cerebral blood flow and oxygen metabolism.
41. 41 Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999; 6:1122-1130. This paper demonstrates improvement in quantitative electroencephalogram abnormalities and cognitive function in hemodialysis patients following normalization of hematocrit.
42. 42 Benz RI, Pressman MR, Hovick ET, Peterson DD. Relationship between anemia of chronic renal failure (ACRAF) and sleep, sleep disorders and daytime alertness: benefits of normalizing hematocrit (the Sleepo trial) [abstract]. J Am Soc Nephrol 1996; 7:1473.
43. 43 Portoles J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29:541-548.
44. 44 Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM. Cardiovascular consequences of correction of anemia of renal failure with erythropoietin. Kidney Int 1993; 44:1309-1315.
45. 45 Vazari ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33:821-828. A comprehensive review of pathophysiology of erythropoietin induced hypertension.
46. 46 Schwartz AB, Prior JE, Mintz GS, et al. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant human erythropoietin. Trans proceedings 1991; 23:1827-1830.
47. 47 Vazari ND, Zhou XJ, Naqvi F, Smith J, Oveisi F, Wang ZQ, Purdy RE. Role of nitric oxide resistance in erythropoietin induced hypertension in rats with chronic renal failure. Am J Physiol 1996; 271:E113-E122.
48. 48 Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994; 4:1874-1878.
49. 49 Jacobs AA, Ouseph R, Erbeck KM, Brier ME. Iron dextran administration is associated with infection in hemodialysis patients [abstract]. J Am Soc Nephrol 1998; 9:252A.
50. 50 Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9:869-876. A multicenter prospective cross-sectional study determining risk factors for bacteremia in hemodialysis patients.